他非诺喹——是重大改进吗？ - Suppr | 超能文献

Tafenoquine - A Radical Improvement?

作者信息

White Nicholas J

机构信息

From Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand, and the Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

出版信息

N Engl J Med. 2019 Jan 17;380(3):285-286. doi: 10.1056/NEJMe1816383.

DOI:10.1056/NEJMe1816383

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Tafenoquine - A Radical Improvement?他非诺喹——是重大改进吗？

N Engl J Med. 2019 Jan 17;380(3):285-286. doi: 10.1056/NEJMe1816383.

2

Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.泰非诺喹与伯氨喹预防间日疟复发。

N Engl J Med. 2019 Jan 17;380(3):229-241. doi: 10.1056/NEJMoa1802537.

3

Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.单次服用他非诺喹预防间日疟原虫疟疾复发。

N Engl J Med. 2019 Jan 17;380(3):215-228. doi: 10.1056/NEJMoa1710775.

4

Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. Reply.

N Engl J Med. 2019 May 9;380(19):1876. doi: 10.1056/NEJMc1902327.

5

Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.他非诺喹（WR238605）三剂方案与低剂量伯氨喹预防间日疟原虫疟疾复发的随机试验。

Clin Infect Dis. 2004 Oct 15;39(8):1095-103. doi: 10.1086/424508. Epub 2004 Sep 24.

6

Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.他非诺喹与伯氨喹预防间日疟原虫疟疾复发的比较

N Engl J Med. 2019 May 9;380(19):1875-1876. doi: 10.1056/NEJMc1902327.

7

Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.

N Engl J Med. 2019 May 9;380(19):1875. doi: 10.1056/NEJMc1902327.

8

Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.泰非醌联合氯喹治疗和预防间日疟（DETECTIVE）：一项多中心、双盲、随机、2b 期剂量选择研究。

Lancet. 2014 Mar 22;383(9922):1049-58. doi: 10.1016/S0140-6736(13)62568-4. Epub 2013 Dec 19.

9

Tafenoquine for the treatment of recurrent Plasmodium vivax malaria.他非诺喹用于治疗间日疟原虫复发性疟疾。

Am J Trop Med Hyg. 2007 Mar;76(3):494-6.

10

The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific.三种不同tafenoquine方案与伯氨喹在西南太平洋地区对间日疟原虫疟疾暴露后预防的疗效和耐受性比较

Trans R Soc Trop Med Hyg. 2008 Nov;102(11):1095-101. doi: 10.1016/j.trstmh.2008.04.024. Epub 2008 Jun 9.

引用本文的文献

1

Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria.在治疗间日疟原虫疟疾中，以平衡疗效与风险为目标的磷酸萘酚喹。

Malar J. 2024 May 13;23(1):145. doi: 10.1186/s12936-024-04924-z.

2

Global perspectives on associations with primaquine metabolism and radical cure.关于伯氨喹代谢与根治关系的全球观点。

Front Pharmacol. 2022 Nov 15;13:752314. doi: 10.3389/fphar.2022.752314. eCollection 2022.

3

Glucose 6 Phosphate Dehydrogenase (G6PD) quantitation using biosensors at the point of first contact: a mixed method study in Cambodia.使用生物传感器在首次接触点定量检测葡萄糖 6 磷酸脱氢酶（G6PD）：柬埔寨的一项混合方法研究。

Malar J. 2022 Oct 4;21(1):282. doi: 10.1186/s12936-022-04300-9.

4

Genetic Variants of Glucose-6-Phosphate Dehydrogenase and Their Associated Enzyme Activity: A Systematic Review and Meta-Analysis.葡萄糖-6-磷酸脱氢酶的基因变异及其相关酶活性：一项系统评价和荟萃分析

Pathogens. 2022 Sep 14;11(9):1045. doi: 10.3390/pathogens11091045.

5

Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone.使用他非诺喹治疗一名患有复发性巴贝斯虫病的患者，该患者具有对阿奇霉素和阿托伐醌耐药的临床及分子证据。

IDCases. 2022 Feb 25;27:e01460. doi: 10.1016/j.idcr.2022.e01460. eCollection 2022.

6

gene resequencing in the Malagasy, a population at the crossroads between Asia and Africa: a pilot study.马达加斯加的基因重测序：一个连接亚非大陆的人群的初步研究。

Pharmacogenomics. 2022 Apr;23(5):315-325. doi: 10.2217/pgs-2021-0146. Epub 2022 Mar 1.

7

Further evidence needed to change policy for the safe and effective radical cure of vivax malaria: Insights from the 2019 annual APMEN Vivax Working Group meeting.改变间日疟安全有效根治政策所需的进一步证据：来自2019年APMEN间日疟工作组年度会议的见解

Asia Pac Policy Stud. 2021 May;8(2):208-242. doi: 10.1002/app5.314. Epub 2021 Jan 12.

8

Opening the policy blackbox: unravelling the process for changing national diagnostic and treatment guidelines for vivax malaria in seven countries.打开政策黑箱：揭示七个国家改变间日疟诊断和治疗指南的过程。

Malar J. 2021 Oct 30;20(1):428. doi: 10.1186/s12936-021-03959-w.

9

Genetic Variation and Its Implication for Vivax Malaria Treatment in Madagascar.马达加斯加间日疟原虫疟疾治疗中的基因变异及其意义

Front Pharmacol. 2021 Apr 20;12:654054. doi: 10.3389/fphar.2021.654054. eCollection 2021.

10

Towards the elimination of Plasmodium vivax malaria: Implementing the radical cure.迈向消除间日疟原虫疟疾：实施根治措施。

PLoS Med. 2021 Apr 23;18(4):e1003494. doi: 10.1371/journal.pmed.1003494. eCollection 2021 Apr.